Last $16.97 USD
Change Today +1.06 / 6.66%
Volume 436.9K
ATRC On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

atricure inc (ATRC) Snapshot

Open
$17.75
Previous Close
$15.91
Day High
$18.07
Day Low
$16.51
52 Week High
01/10/14 - $23.00
52 Week Low
08/28/13 - $8.48
Market Cap
465.1M
Average Volume 10 Days
169.3K
EPS TTM
$-0.68
Shares Outstanding
27.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATRICURE INC (ATRC)

Related News

No related news articles were found.

atricure inc (ATRC) Related Businessweek News

No Related Businessweek News Found

atricure inc (ATRC) Details

AtriCure, Inc., a medical device company, provides atrial fibrillation solutions worldwide. It provides isolator bipolar radio-frequency (RF) ablation clamps that are used for ablation during open-heart procedures; and ablation and sensing unit, a compact power generator that provides the RF energy for its clamps, multifunctional pens, and coolrail linear ablation devices. The company also offers AtriCure Switch Box, a compact switch box, which offers the technology needed for the dual pulsing electrodes in isolator synergy clamps; isolator multifunctional pens that enable surgeons to evaluate cardiac arrhythmias, as well as to perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and coolrail linear ablation device, a disposable linear RF ablation device that allows physicians to create an expanded cardiac ablation lesion set during minimally invasive procedures. In addition, it provides RF ablation devices, such as COBRA Fusion Surgical Ablation System; COBRA Revolution Bipolar Clamp; COBRA Electrosurgical Unit; COBRA Monopolar Surgical Devices; and COBRA AFfirm Bipolar Pacing Probe. Further, the company offers cryoablation system, which is used for afib ablation treatment during certain open-heart procedures; and AtriClip System that is designed to exclude the left atrial appendage by implanting the device during concomitant open surgical procedures. Additionally, it sells technologies, including Lumitip dissector to separate tissues to provide access to anatomical structures that are targeted for ablation; the MicroPace ORLab system, a stimulating, mapping, and recording system; and Estech valve surgical devices that provide solutions with exposure and instrumentation for valve procedures using minimally invasive access. The company sells its products to hospitals and medical centers through independent distributors and direct sales personnel. AtriCure, Inc. is headquartered in West Chester, Ohio.

320 Employees
Last Reported Date: 03/11/14

atricure inc (ATRC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $500.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $212.5K
Senior Vice President of Operations & Quality...
Total Annual Compensation: $278.1K
Vice President and General Manager of Interna...
Total Annual Compensation: $378.8K
Senior Vice President of Sales & Marketing
Total Annual Compensation: $300.0K
Compensation as of Fiscal Year 2013.

atricure inc (ATRC) Key Developments

AtriCure, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Updates Revenue Guidance and Provides Earnings Guidance for the Fiscal Year 2014

AtriCure, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced total revenue was $26,514,000 compared to $20,429,000 for the same period a year ago. Loss from operations was $2,853,000 compared to $1,639,000 for the same period a year ago. Loss before income tax expense was $2,687,000 compared to $1,786,000 for the same period a year ago. Net loss was $2,692,000 compared to $1,791,000 for the same period a year ago. Basic and diluted net loss per share was $0.10 compared to $0.09 for the same period a year ago. Non-GAAP adjusted loss (adjusted LBITDA) was $2,537,000 compared to non-GAAP adjusted earnings (adjusted LBITDA) of $323,000 for the same period a year ago. For the six months, the company announced total revenue was $51,361,000 compared to $39,859,000 for the same period a year ago. Loss from operations was $10,778,000 compared to $3,439,000 for the same period a year ago. Loss before income tax expense was $10,369,000 compared to $3,724,000 for the same period a year ago. Net loss was $10,401,000 compared to $3,734,000 for the same period a year ago. Basic and diluted net loss per share was $0.40 compared to $0.19 for the same period a year ago. Net cash used in operating activities was $18,373,000 compared to $2,832,000 for the same period a year ago. Purchases of property and equipment were $2,475,000 compared to $1,191,000 for the same period a year ago. Non-GAAP adjusted loss (adjusted LBITDA) was $7,235,000 compared to non-GAAP adjusted loss (adjusted LBITDA) of $1,144,000 for the same period a year ago. The company updated revenue guidance and provided earnings guidance for the fiscal year 2013. For the year, the company raising the company guidance for 2014 to a revenue range of $103 million to $105 million, reflecting approximately 26% to 28% year-over-year growth, up from the company previous guidance. Adjusted EBITDA, a non-GAAP measure, is expected to be a loss in the range of $9 million to $10 million for 2014, of which approximately $3.5 million of expense will be related to the Estech transaction. AtriCure expects the Estech transaction to be dilutive to earnings in 2014 and accretive in 2015 and beyond. The company expects R&D to be 17% to 19% of sales, and SG&A to be roughly 71% to 73% of sales in 2014.

AtriCure, Inc. to Report Q2, 2014 Results on Jul 24, 2014

AtriCure, Inc. announced that they will report Q2, 2014 results at 8:01 PM, GMT Standard Time on Jul 24, 2014

AtriCure, Inc., Q2 2014 Earnings Call, Jul 24, 2014

AtriCure, Inc., Q2 2014 Earnings Call, Jul 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATRC:US $16.97 USD +1.06

ATRC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CryoLife Inc $9.75 USD -0.28
Sequenom Inc $3.67 USD -0.01
STAAR Surgical Co $12.77 USD +0.14
SurModics Inc $19.56 USD -0.19
Vascular Solutions Inc $24.65 USD +0.05
View Industry Companies
 

Industry Analysis

ATRC

Industry Average

Valuation ATRC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.9x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATRICURE INC, please visit www.atricure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.